Old Evaluation Systems Are Inadequate For AI Health Care And Drug Development Ecosystem

By | May 5, 2019

a new open-access quarterly report on the AI for Drug Discovery Industry. This 108-page report provides a comprehensive overview of the AI Pharma landscape through Q1 2019. This report features an analysis of 350 investors, 50 corporations and 150 companies active in the sector, and a list of 30 leading R&D centers that provide essential research in this area. The report also covers the most important events that took place in the industry in Q1 2019.

According to the new report, investment in AI for Drug Discovery startups increased from $ 200 million in 2015 to over $ 700 million in 2018. There is considerable investment interest in this area which is in the scope of the 350 investment companies, 30 more since the last quarter of 2018. Although there is no consensus so far among analysts regarding the expected valuation of the industry, estimates range from $ 5 billion to $ 20 billion by 2024.

According to the new report, investment in AI for Drug Discovery startups increased from $ 200 million in 2015 to over $ 700 million in 2018

DKA

As the research indicates, the declining R&D efficiency of Biopharma companies remains a primary concern among all parties in the industry with a continuous decline recorded during the last eight years. The antibiotics industry is closely affected by this decline and it causes severe concerns about the future. The number of new antibiotics approved by the US Food and Drug Administration (FDA) has declined between 1983 and 2012, according to an OECD report on how to tackle antimicrobial resistance. Also, according to 2016 data, there are fewer big pharma companies with an active antibiotic R&D pipeline. There are only six such companies, whereas in 1990 there were 18. New antibiotics are becoming increasingly challenging to discover and typically only 1.5 percent of antibiotics in preclinical development finally reach the market.

AI technologies could offer solutions to the problem allowing for faster drug development and by cutting down on the cost of preclinical research. The emerging field of precision medicine raises hopes to companies and patients that the future will give more opportunities to overcome the obstacles posed by lack of resources or expertise.

” readability=”53.374034003091″>

Early stage startups are assessed using 100 parameters. Advanced stage companies are assessed using more than 300 settings.

DKA

Nowadays there is a storm of news about the use of AI technology in the broader field of health care because of its cosmogenic activity to reshape it. Long established organizations, as well as newly founded startups, compete with each other who will catch the train of innovation to reach first the station of significant results. The weakest companies need the right financial boosting that will turn their idea into an innovative product or service. Usually, the necessary encouragement is given by investors who believe in the idea and their business plan. This means that they have to analyze complex datasets to spot the most plausible propositions.

An evaluation tool would be an invaluable help for the investors as well as for the whole market which needs a broader view of recent developments to identify trends, fields with margins for further growth, but also areas where the market is already saturated. Deep Knowledge Analytics has materialized a platform with all the features mentioned above. It makes use of multiple parameters and applies quantified metrics to perform an in-depth comparative analysis to differentiate levels of maturity, business development, clear scientific advantages, and technological standards in a very objective way. Early stage startups are assessed using 100 parameters. Advanced stage companies are assessed using more than 300 settings.

These companies are shaping the market of AI in healthcare and drug discovery

DKA

Based on this application, last April the company published a new open-access quarterly report on the AI for Drug Discovery Industry. This 108-page report provides a comprehensive overview of the AI Pharma landscape through Q1 2019. This report features an analysis of 350 investors, 50 corporations and 150 companies active in the sector, and a list of 30 leading R&D centers that provide essential research in this area. The report also covers the most important events that took place in the industry in Q1 2019.

According to the new report, investment in AI for Drug Discovery startups increased from $ 200 million in 2015 to over $ 700 million in 2018. There is considerable investment interest in this area which is in the scope of the 350 investment companies, 30 more since the last quarter of 2018. Although there is no consensus so far among analysts regarding the expected valuation of the industry, estimates range from $ 5 billion to $ 20 billion by 2024.

According to the new report, investment in AI for Drug Discovery startups increased from $ 200 million in 2015 to over $ 700 million in 2018

DKA

As the research indicates, the declining R&D efficiency of Biopharma companies remains a primary concern among all parties in the industry with a continuous decline recorded during the last eight years. The antibiotics industry is closely affected by this decline and it causes severe concerns about the future. The number of new antibiotics approved by the US Food and Drug Administration (FDA) has declined between 1983 and 2012, according to an OECD report on how to tackle antimicrobial resistance. Also, according to 2016 data, there are fewer big pharma companies with an active antibiotic R&D pipeline. There are only six such companies, whereas in 1990 there were 18. New antibiotics are becoming increasingly challenging to discover and typically only 1.5 percent of antibiotics in preclinical development finally reach the market.

AI technologies could offer solutions to the problem allowing for faster drug development and by cutting down on the cost of preclinical research. The emerging field of precision medicine raises hopes to companies and patients that the future will give more opportunities to overcome the obstacles posed by lack of resources or expertise.

Forbes – Healthcare